Pharmacogenetic Approaches to Cognitive Enhancement in Schizophrenia

REFERENCES

• Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009;78:285–97.
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321–30.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J, Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018–28.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology (Berl) 2003;169:404–11.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Meltzer H, Simpson GM, Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004;66:101–13.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005;162:1888–95.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Burdick KE, Razi K, Bates JA, Sanders M, Kane JM. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? Schizophr Res 2006;87:181–4.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM, et al.; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633– 47.
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Goldman RS, Burdick KE, Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64:1115–22.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Malhotra AK, Meltzer HY, Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33:1217–28.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780–96.
   PubMed Web of Science ®Google Scholar
• Glahn DC, Almasy L, Blangero J, Adjudicating neurocognitive endophenotypes for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007;144B:242–9.
   PubMedGoogle Scholar
• Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009;35:528–48.
   PubMed Web of Science ®Google Scholar
• Lencz T, Smith CW, McLaughlin D, Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 2006;59:863–71.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Robinson D, Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000;57:549–59.
   Google Scholar
• Trandafir A, Meary A, Schurhoff F, et al. Memory tests in first-degree adult relatives of schizophrenic patients: a meta-analysis. Schizophr Res 2006;81:217–26.
   PubMed Web of Science ®Google Scholar
• Toulopoulou T, Picchioni M, Rijsdijk F, Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry 2007;64:1348–55.
   PubMed Web of Science ®Google Scholar
• Need AC, Attix DK, McEvoy JM, A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet 2009;18:4650–61.
   PubMed Web of Science ®Google Scholar
• McClay JL, Adkins DE, Aberg K, Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011;36:616–26.
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609–15.
   PubMed Web of Science ®Google Scholar
• Bertolino A, Caforio G, Blasi G, Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004;161:1798–805.
   PubMed Web of Science ®Google Scholar
• Weickert TW, Goldberg TE, Mishara A, Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004;56:677–82.
   PubMed Web of Science ®Google Scholar
• Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007;90:86–96.
   PubMed Web of Science ®Google Scholar
• Dickinson D, Elvevåg B. Genes, cognition and brain through a COMT lens. Neuroscience 2009;164:72–87.
   PubMed Web of Science ®Google Scholar
• Fan JB, Zhang CS, Gu NF, Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005;57:139–44.
   PubMed Web of Science ®Google Scholar
• Egan MF, Goldberg TE, Kolachana BS, Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917–22.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Volavka J, Czobor P, Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701–7.
   PubMed Web of Science ®Google Scholar
• Rosa A, Peralta V, Cuesta MJ, New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004;161:1110–2.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652–4.
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Yu YW, Chen TJ, Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci Lett 2003;338:123–6.
   PubMedGoogle Scholar
• Chen J, Lipska BK, Halim N, Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807–21.
   PubMed Web of Science ®Google Scholar
• Mattay VS, Goldberg TE, Fera F, Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003;100:6186–91.
   PubMed Web of Science ®Google Scholar
• Apud JA, Mattay V, Chen J, Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007;32:1011–20.
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition.Adv Pharmacol 1998;42:707–11.
   PubMedGoogle Scholar
• Liu L, Wong TP, Pozza MF, Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 2004;304:1021–4.
   PubMed Web of Science ®Google Scholar
• Cotman CW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988;11:61–80.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Pinals DA, Weingartner H, NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301–7.
   PubMed Web of Science ®Google Scholar
• Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psych 1998;44:1081–9.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005;57:577–85.
   PubMed Web of Science ®Google Scholar
• Kantrowitz, JT, Malhotra, AK, Cornblatt, B, High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010;121:125–30.
   PubMed Web of Science ®Google Scholar
• Tsai G, Lane HY, Yang P, Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452–6.
   PubMed Web of Science ®Google Scholar
• Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006;19:158–64.
   PubMed Web of Science ®Google Scholar
• Burdick KE, Lencz T, Funke B, Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet 2006;15:1563–8.
   PubMed Web of Science ®Google Scholar
• Burdick KE, Goldberg TE, Funke B, DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res 2007;89:169–72.
   PubMed Web of Science ®Google Scholar
• Donohoe G, Morris DW, Clarke S, Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007;45:454–8.
   PubMed Web of Science ®Google Scholar
• Stefanis NC, Trikalinos TA, Avramopoulos D, Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol Psychiatry 2007;62:784–92.
   PubMedGoogle Scholar
• Zinkstok JR, de Wilde O, van Amelsvoort TA, Tanck MW, Baas F, Linszen DH. Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. Behav Brain Funct 2007;3:19.
   PubMedGoogle Scholar
• Luciano M, Miyajima F, Lind PA, Variation in the dysbindin gene and normal cognitive function in three independent population samples. Genes Brain Behav 2009;8:218–27.
   PubMedGoogle Scholar
• Hashimoto R, Noguchi H, Hori H, A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. World J Biol Psychiatry 2010;11:431–8.
   PubMed Web of Science ®Google Scholar
• Wolf C, Jackson MC, Kissling C, Thome J, Linden DE. Dysbindin-1 genotype effects on emotional working memory. Mol Psychiatry 2011;16:145–55.
   PubMed Web of Science ®Google Scholar
• Karlsgodt KH, Robleto K, Trantham-Davidson H, Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 2011;69:28–34.
   PubMed Web of Science ®Google Scholar
• Weickert CS, Straub RE, McClintock BW, Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004;61:544–55.
   PubMed Web of Science ®Google Scholar
• Bray NJ, Preece A, Williams NM, Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression.Hum Mol Genet 2005;14:1947–54.
   PubMed Web of Science ®Google Scholar
• Numakawa T, Yagasaki Y, Ishimoto T, Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004;13:2699–2708.
   PubMed Web of Science ®Google Scholar
• Dickman DK, Davis GW. The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science 2009;326:1127–30.
   PubMed Web of Science ®Google Scholar
• Tang TT, Yang F, Chen BS, Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression. Proc Natl Acad Sci U S A 2009;106:21395–400.
   PubMedGoogle Scholar
• Papaleo F, Weinberger DR. Dysbindin and schizophrenia: it's dopamine and glutamate all over again. Biol Psychiatry 2011;69:2–4.
   PubMed Web of Science ®Google Scholar
• Funke B, Finn CT, Plocik AM, Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet 2004;5:891–8.
   Google Scholar
• Posthuma D, Luciano M, Geus EJ, A genomewide scan for intelligence identifies quantitative trait Loci on 2q and 6p. Am J Hum Genet 2005;77: 318–26.
   PubMed Web of Science ®Google Scholar
• Hallmayer JF, Kalaydjieva L, Badcock J, Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet 2005;77: 468–76.
   PubMed Web of Science ®Google Scholar
• Williams NM, Preece A, Morris DW, Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry 2004;61:336–44.
   PubMedGoogle Scholar
• Zhang JP, Burdick KE, Lencz T, Malhotra AK. Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biol Psychiatry 2010;68:1126–33.
   PubMedGoogle Scholar
• Chumakov I, Blumenfeld M, Guerassimenko O, Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675–80.
   PubMed Web of Science ®Google Scholar
• Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006;60:106–14.
   PubMedGoogle Scholar
• Opgen-Rhein C, Lencz T, Burdick KE, Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. Schizophr Res 2008;103:169–77.
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Straub RE, Callicott JH, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006;31:2022–32.
   PubMed Web of Science ®Google Scholar
• O'Donovan MC, Craddock N, Norton N, et al.; Molecular Genetics of Schizophrenia Collaboration. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40:1053–5.
   PubMed Web of Science ®Google Scholar
• Riley B, Thiselton D, Maher BS, Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Mol Psychiatry 2010;15:29– 37.
   PubMed Web of Science ®Google Scholar
• Steinberg S, Mors O, Børglum AD, Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry 2011;16:59–66.
   PubMed Web of Science ®Google Scholar
• Williams HJ, Norton N, Dwyer S, et al.; Molecular Genetics of Schizophrenia Collaboration (MGS), International Schizophrenia Consortium (ISC), SGENE-plus, GROUP, Malhotra AK, Riley B, Kendler KS, et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2011;16:429–41.
   PubMed Web of Science ®Google Scholar
• Esslinger C, Walter H, Kirsch P, Neural mechanisms of a genome-wide supported psychosis variant. Science 2009;324:605.
   PubMed Web of Science ®Google Scholar
• Lencz T, Szeszko PR, Derosse P, A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 2010;35:2284–91.
   PubMedGoogle Scholar
• Walter H, Schnell K, Erk S, Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. Mol Psychiatry 2011;16:462–70.
   PubMed Web of Science ®Google Scholar
• Walters JT, Corvin A, Owen MJ, Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry 2010;67:692–700.
   PubMed Web of Science ®Google Scholar